Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to $65.2 million.

  • Burning Rock Biotech's Cash & Equivalents fell 8.15% to $65.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year decrease of 8.15%. This contributed to the annual value of $71.2 million for FY2024, which is 17.79% down from last year.
  • As of Q2 2025, Burning Rock Biotech's Revenue - Interest and Investment Income stood at $564.2 million, which was up 597.79% from $80.9 million recorded in Q4 2024.
  • In the past 5 years, Burning Rock Biotech's Cash & Equivalents ranged from a high of $1.0 billion in Q3 2022 and a low of $65.2 million during Q3 2025.
  • Its 3-year average for Cash & Equivalents is $302.3 million, with a median of $115.5 million in 2023.
  • As far as peak fluctuations go, Burning Rock Biotech's Cash & Equivalents surged by 12,106.40% in 2021, and later slumped by 90.01% in 2024.
  • Burning Rock Biotech's Revenue - Interest and Investment Income (Quarterly) stood at $288.6 million in 2021, then followed by $213.8 million in 2022, then followed by $80.9 million in 2024, then followed by $564.2 million in 2025.
  • Its last three reported values are $65.2 million in Q3 2025, $455.0 million for Q2 2025, and $495.1 million during Q1 2025.